Aapkes, S. E.
Bernts, L. H. P.
van den Berg, A. P.
van den Berg, M.
Blokzijl, H.
Cantineau, A. E. P.
van Gastel, M. D. A.
de Haas, R. J.
Kappert, P.
Müller, R. U.
Nevens, F.
Torra, R.
Visser, A.
Drenth, J. P. H.
Gansevoort, R. T.
Funding for this research was provided by:
ZonMW (10140261910001)
AbbVie (SA-003047 (ACA-NETH-20-01))
Article History
Received: 31 January 2022
Accepted: 6 February 2022
First Online: 25 February 2022
Declarations
:
: Ethics approval was obtained before start of the trial by the Internal Review Board (IRB) from the University Medical Center of Groningen, METC number METc 2021/119. All participants must give their voluntary and written informed consent before any study related procedures could take place.
: Not applicable.
: Dr. Gansevoort received grant support and fees for serving on advisory boards and steering committees from Galapagos, IPSEN, Otsuka Pharmaceuticals and Sanofi-Genzyme. In addition, Dr. Gansevoort holds the Orphan Medicinal Product Designation status at the European Medicines Agency for lanreotide as treatment for kidney function decline in ADPKD (EMA/OD/027/15). Dr. Drenth has received grant support and fees for serving on advisory boards and consultancy from IPSEN and Novartis. All money is paid to their institutions. No other potential conflict of interest relevant to this article was reported. The Dept. II of Internal Medicine (University of Cologne) received research funding from Otsuka Pharmaceuticals and ThermoFisherScientific.